Loren Data's SAM Daily™

SAMDAILY.US - ISSUE OF APRIL 15, 2023 SAM #7809
SOLICITATION NOTICE

65 -- License Renewal for Protein Expressing Cell Line

Notice Date

4/13/2023 6:07:19 AM
 

Notice Type

Presolicitation
 

NAICS

325414 — Biological Product (except Diagnostic) Manufacturing
 

Contracting Office

NATIONAL INSTITUTES OF HEALTH NIAID BETHESDA MD 20892 USA
 

ZIP Code

20892
 

Solicitation Number

NOI-NIAID-23-2168820
 

Response Due

4/28/2023 7:00:00 AM
 

Point of Contact

Seth Schaffer, Phone: 3017616205, Tamara McDermott, Phone: 4063757487
 

E-Mail Address

seth.schaffer@nih.gov, tamara.mcdermott@nih.gov
(seth.schaffer@nih.gov, tamara.mcdermott@nih.gov)
 

Description

THIS IS A NOTICE OF INTENT AND NOT A REQUEST FOR QUOTATIONS This notice is published in accordance with Federal Acquisition Regulation (FAR) 5.101(a)(1) requiring the dissemination of information regarding proposed contract actions. This is a Notice of Intent to award a sole source, firm-fixed price purchase order under the authority of 41 U.S.C. 3304(a)(1), as implemented by FAR 13.106-1(b)(2) and 13.501(a) - Only One Responsible Source and No Other Supplies or Service Will Satisfy Agency Requirements and is not a request for competitive quotes.� The National Institute of Allergy and Infectious Diseases (NIAID), Division of AIDS (DAIDS) intends to negotiate on a sole source basis with DNA TwoPointO Inc., Doing Business As ATUM Biosciences, at 37950 Central CT, Newark, California 94560-3463, United States. This acquisition is for a license to the proprietary cell line for the production of an engineered antibody (PGDM1400.LS) to support ongoing AIDS clinical trials. The order will consist of a one-year base period followed by four (4) one-year option periods. The Vaccine Translational Research Branch (VTRB) has worked with antibodies produced from cell lines created from ATUM Leap-In Transposon technology and has already performed gene synthesis and cell line development work. DAIDS requires a license for this technology to be able to continue to access ATUM�s cell line used to develop and manufacture the PGDM1400.LS antibody for ongoing clinical trials.� This cell line includes ATUM�s Leap-In Transposon technology, which is proprietary to ATUM and can only be licensed through ATUM directly. ATUM�s technology uses transposons, which preferentially integrate in transcriptionally active chromatin at specific sites. This required element of the technology is necessary as the research requires the acceleration of the generation of highly productive stable cell pools and lines. ATUM is the only source capable of providing the license for this cell line with Leap-In Transposon technology. Period of Performance: The period of performance for this requirement is May 14, 2024 � May 13, 2024 for the base year, with a maximum potential period of performance from May 14, 2023 � May 13, 2028 if all options are exercised. The North American Industry Classification (NAICS) code for this acquisition is 325414 - Biological Product (Except Diagnostic) Manufacturing), which has a size standard of 1250 employees. ATUM Biosciences is a small business under this NAICS. � This will be the only notice of the Government's intent to solicit, negotiate, and award to one source to satisfy this requirement. �The Government plans to award a contract for this requirement within 24 days of this notice. This acquisition will be made pursuant to the statutory authorization in 41 USC 3304(a)(1), FAR Part 12 � Acquisition for Commercial Items, and FAR Part 13.106-1(b)(2). THIS IS NOT A SOLICITATION FOR COMPETITIVE QUOTATIONS.� All responsible sources that can provide the Protein Expressing Cell Lines license for broadly neutralizing antibody PGDM1400.LS should submit a capability statement via email to Seth Schaffer at Seth.Schaffer@nih.gov by 10:00am EST on Friday, April 28, 2023. Such documentation shall be evaluated solely for the purpose of determining whether or not to conduct this procurement on a competitive basis. �A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.� Any responses received by NIAID after this date and exact time specified are late and will not be considered.� This notice does not obligate the Government to award a contract or otherwise pay for any information provided in response. �The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. �Any organization responding to this notice should ensure that its and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. �Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. For additional information or to submit responses, please contact Seth Schaffer, Contract Specialist, at seth.schaffer@nih.gov.
 

Web Link

SAM.gov Permalink
(https://sam.gov/opp/580532fcd4ab4b6f984bc57c78bf1b54/view)
 

Place of Performance

Address: Rockville, MD 20852, USA

Zip Code: 20852

Country: USA
 

Record

SN06650449-F 20230415/230413230116 (samdaily.us)
 

Source

SAM.gov Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's SAM Daily Index Page |